Kobayashi Pharmaceutical Co., Ltd.
4967
Rang in Aktien
#4483
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries,... Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
Aktienkurs
$45.65
Marktkapitalisierung
$3.39B
Veränderung (1 Tag)
-0.40%
Veränderung (1 Jahr)
30.30%
Land
JP
Handel Kobayashi Pharmaceutical Co., Ltd. (4967)
Kategorie
Consumer Defensive
Gewinn für Kobayashi Pharmaceutical Co., Ltd. (4967)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Kobayashi Pharmaceutical Co., Ltd. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Kobayashi Pharmaceutical Co., Ltd. von 2005 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2025 | $23.86M | -73.08% |
| 2024 | $88.62M | -54.65% |
| 2023 | $195.41M | -8.33% |
| 2022 | $213.16M | -11.21% |
| 2021 | $240.08M | -6.94% |
| 2020 | $257.99M | 4.61% |
| 2019 | $246.62M | 6.86% |
| 2018 | $230.79M | 15.20% |
| 2017 | $200.34M | 12.22% |
| 2016 | $178.53M | 6.77% |
| 2015 | $167.22M | -12.30% |
| 2014 | $190.68M | -4.69% |
| 2013 | $200.06M | -16.27% |
| 2012 | $238.92M | 50.28% |
| 2011 | $158.98M | 2.08% |
| 2010 | $155.74M | -5.80% |
| 2009 | $165.34M | 4.35% |
| 2008 | $158.45M | 16.55% |
| 2007 | $135.95M | 14.16% |
| 2006 | $119.09M | -0.17% |
| 2005 | $119.29M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $20.38B | - |
US
|
|
| $9.83B | - |
FR
|
|
| $2.94B | - |
US
|
|
| $1.55B | - |
IN
|
|
| $517.00M | - |
US
|
